'Neo-FAC' (5-fluorouracil, doxorubicin, and cyclophosphamide) for poor- prognosis stage IV breast cancer: A Southwest Oncology Group phase II study

Georgiana K. Ellis, Stephanie Green, Robert B. Livingston, Michael J. Kraut, H. Irving Pierce, Jorge C. Paradelo, Sarah A. Taylor, Silvana Martino

Research output: Contribution to journalArticle

1 Scopus citations

Fingerprint Dive into the research topics of ''Neo-FAC' (5-fluorouracil, doxorubicin, and cyclophosphamide) for poor- prognosis stage IV breast cancer: A Southwest Oncology Group phase II study'. Together they form a unique fingerprint.

Medicine & Life Sciences